Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 50/100

Failure Rate

14.8%

51 terminated/withdrawn out of 345 trials

Success Rate

84.5%

-2.0% vs industry average

Late-Stage Pipeline

13%

45 trials in Phase 3/4

Results Transparency

60%

168 of 279 completed trials have results

Key Signals

168 with results39 terminated12 withdrawn

Enrollment Performance

Analytics

Phase 1

161(50.5%)

Phase 2

107(33.5%)

Phase 3

28(8.8%)

Phase 4

17(5.3%)

N/A

4(1.3%)

Early Phase 1

2(0.6%)

319Total

Phase 1(161)

Phase 2(107)

Phase 3(28)

Phase 4(17)

+2 more

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (345)

Showing 20 of 345 trials

NCT03381274Phase 1Active Not Recruiting

Oleclumab (MEDI9447) Epidermal Growth Factor Receptor Mutant (EGFRm) Non-small Cell Lung Cancer (NSCLC) Novel Combination Study

Role: lead

NCT01843374Phase 2Active Not Recruiting

Randomized, Double-blind Study Comparing Tremelimumab to Placebo in Subjects With Unresectable Malignant Mesothelioma

Role: lead

NCT04068610Phase 1Active Not Recruiting

COLUMBIA-1: Novel Oncology Therapies in Combination With Chemotherapy and Bevacizumab as First- Line Therapy in MSS-CRC

Role: lead

NCT02519348Phase 2Active Not Recruiting

A Study of Durvalumab or Tremelimumab Monotherapy, or Durvalumab in Combination With Tremelimumab or Bevacizumab in Advanced Hepatocellular Carcinoma

Role: lead

NCT02499328Phase 1Completed

Study to Assess MEDI4736 With Either AZD9150 or AZD5069 in Advanced Solid Tumors & Relapsed Metastatic Squamous Cell Carcinoma of Head & Neck

Role: collaborator

NCT03373045Completed

Observational Study of Characteristics, Treatment and Outcomes With Severe Asthma in the United States (CHRONICLE)

Role: collaborator

NCT02938793Phase 2Terminated

Durvalumab in Combination With Tremelimumab in Subjects With Advanced Rare Solid Tumors

Role: collaborator

NCT04522323Phase 1Active Not Recruiting

A Study to Evaluate MEDI5752 and Axitinib in Subjects With Advanced Renal Cell Carcinoma

Role: lead

NCT02671435Phase 1Active Not Recruiting

A Study of Durvalumab (MEDI4736) and Monalizumab in Solid Tumors

Role: lead

NCT03215095Early Phase 1Active Not Recruiting

RAI Plus Immunotherapy for Recurrent/Metastatic Thyroid Cancers

Role: collaborator

NCT03336606Phase 1Active Not Recruiting

Study of MEDI0562 Prior to Surgical Resection in Head and Neck Squamous Cell Carcinoma (HNSCC) or Melanoma

Role: collaborator

NCT02815995Phase 2Completed

Multi-Arm Study to Test the Efficacy of Immunotherapeutic Agents in Multiple Sarcoma Subtypes

Role: collaborator

NCT02678182Phase 2Active Not Recruiting

Planning Treatment for Oesophago-gastric Cancer: a Maintenance Therapy Trial

Role: collaborator

NCT02153151Completed

Measuring Biomarker Response to AMP-514 in Blood Samples From Patients With Solid Tumors Undergoing Radiotherapy

Role: collaborator

NCT01997450Terminated

A Case Control Study of the Effectiveness of Q/LAIV Versus Inactivated Influenza Vaccine and No Vaccine in Subjects 2-17 Years of Age

Role: lead

NCT02780674Phase 1Completed

A Phase 1 Study of MEDI7734 in Type I Interferon-Mediated Autoimmune Diseases

Role: collaborator

NCT03555994Phase 2Completed

A Study to Investigate the Effect of MEDI0382 on Hepatic Glycogen Metabolism in Overweight and Obese Subjects With Type 2 Diabetes Mellitus.

Role: lead

NCT03773172Phase 2Terminated

Study to Evaluate the Effects of MEDI6012 on Apolipoprotein B100 Metabolism

Role: collaborator

NCT03822351Phase 2Completed

Durvalumab Alone or in Combination With Novel Agents in Subjects With NSCLC

Role: lead

NCT03946800Phase 1Completed

A Study of MEDI1191 in Sequential and Concurrent Combination With Durvalumab in Subjects With Advanced Solid Tumors

Role: lead